ABSTRACT

A novel HPLC method was developed and validated for simultaneous estimation of ritonavir, lopinavir and efavirenz in tablet dosage form. In this method, an analytical shimadzu (150mm x 3.0mm x 3µm) column was used for chromatographic separation with a mixture of ACN and 0.02M potassium Di hydrogen Ortho phosphate as the mobile phase in the ratio 60:40%V/V. The flow rate of mobile phase was maintained at 1.4ml/min. The UV detection was performed at 233nm. Injection volume was set at 20µl. Run time was maintained at 10minutes. Retention time of Ritonavir, Lopinavir and Efavirenz were 5.919, 6.957, 8.176.The % RSD of Ritonavir, Lopinavir and Efavirenz was found to be 0.32, 0.44 and 0.39. The method was fully validated in terms of system suitability, specificity, linearity, precision, accuracy, and robustness, limit of detection and limit of quantification according to official guidelines of ICH Q2 (R1). Keywords: ICH, Ritonavir, Lopinavir and Efavirenz, shimadzu
Publication date: 01/02/2022

https://ijbpas.com/pdf/2022/February/MS_IJBPAS_2022_5867.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2022/11.2.5867